Physiology of cardiomyocyte injury in COVID-19.


Journal

medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986

Informations de publication

Date de publication:
16 Nov 2020
Historique:
pubmed: 18 11 2020
medline: 18 11 2020
entrez: 17 11 2020
Statut: epublish

Résumé

COVID-19 affects multiple organs. Clinical data from the Mount Sinai Health System shows that substantial numbers of COVID-19 patients without prior heart disease develop cardiac dysfunction. How COVID-19 patients develop cardiac disease is not known. We integrate cell biological and physiological analyses of human cardiomyocytes differentiated from human induced pluripotent stem cells (hiPSCs) infected with SARS-CoV-2 in the presence of interleukins, with clinical findings, to investigate plausible mechanisms of cardiac disease in COVID-19 patients. We infected hiPSC-derived cardiomyocytes, from healthy human subjects, with SARS-CoV-2 in the absence and presence of interleukins. We find that interleukin treatment and infection results in disorganization of myofibrils, extracellular release of troponin-I, and reduced and erratic beating. Although interleukins do not increase the extent, they increase the severity of viral infection of cardiomyocytes resulting in cessation of beating. Clinical data from hospitalized patients from the Mount Sinai Health system show that a significant portion of COVID-19 patients without prior history of heart disease, have elevated troponin and interleukin levels. A substantial subset of these patients showed reduced left ventricular function by echocardiography. Our laboratory observations, combined with the clinical data, indicate that direct effects on cardiomyocytes by interleukins and SARS-CoV-2 infection can underlie the heart disease in COVID-19 patients.

Identifiants

pubmed: 33200140
doi: 10.1101/2020.11.10.20229294
pmc: PMC7668750
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Commentaires et corrections

Type : UpdateIn

Déclaration de conflit d'intérêts

Conflict of interest. The A.G.-S. laboratory has received research support from Pfizer, Senhwa Biosciences, Kenall Manufacturing, Avimex, Johnson & Johnson, Dynavax and 7Hills Pharma. Adolfo García-Sastre has consulting agreements for the following companies involving cash and/or stock: Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Vaxalto, Pagoda, Accurius and Esperovax. Ravi Iyengar has a consulting agreement with Tectonic Therapeutics.

Auteurs

Mustafa M Siddiq (MM)

Department of Pharmacological Sciences, and Institute for Systems Biomedicine, Icahn School of Medicine at Mount Sinai, New York NY 10029.

Angel T Chan (AT)

Department of Pharmacological Sciences, and Institute for Systems Biomedicine, Icahn School of Medicine at Mount Sinai, New York NY 10029.
Departments of Medicine and Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.

Lisa Miorin (L)

Department of Microbiology and Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York NY 10029.

Arjun S Yadaw (AS)

Department of Pharmacological Sciences, and Institute for Systems Biomedicine, Icahn School of Medicine at Mount Sinai, New York NY 10029.

Kristin G Beaumont (KG)

Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York NY 10029.

Thomas Kehrer (T)

Department of Microbiology and Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York NY 10029.
Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York NY 10029.

Kris M White (KM)

Department of Microbiology and Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York NY 10029.

Anastasija Cupic (A)

Department of Microbiology and Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York NY 10029.

Rosa E Tolentino (RE)

Department of Pharmacological Sciences, and Institute for Systems Biomedicine, Icahn School of Medicine at Mount Sinai, New York NY 10029.

Bin Hu (B)

Department of Pharmacological Sciences, and Institute for Systems Biomedicine, Icahn School of Medicine at Mount Sinai, New York NY 10029.

Alan D Stern (AD)

Department of Pharmacological Sciences, and Institute for Systems Biomedicine, Icahn School of Medicine at Mount Sinai, New York NY 10029.

Iman Tavassoly (I)

Department of Pharmacological Sciences, and Institute for Systems Biomedicine, Icahn School of Medicine at Mount Sinai, New York NY 10029.

Jens Hansen (J)

Department of Pharmacological Sciences, and Institute for Systems Biomedicine, Icahn School of Medicine at Mount Sinai, New York NY 10029.

Pedro Martinez (P)

Department of Pharmacological Sciences, and Institute for Systems Biomedicine, Icahn School of Medicine at Mount Sinai, New York NY 10029.

Nicole Dubois (N)

Department of Cell Developmental and Regenerative Biology and Black Family Stem Cell Center, Icahn School of Medicine at Mount Sinai, New York NY 10029.

Christoph Schaniel (C)

Division of Hematology & Oncology Department of Medicine and Black Family Stem Cell Center, Icahn School of Medicine at Mount Sinai, New York NY 10029.

Rupa Iyengar-Kapuganti (R)

Division of Cardiology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York NY 10029.

Nina Kukar (N)

Division of Cardiology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York NY 10029.

Gennaro Giustino (G)

Division of Hematology & Oncology Department of Medicine and Black Family Stem Cell Center, Icahn School of Medicine at Mount Sinai, New York NY 10029.

Karan Sud (K)

Division of Cardiology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York NY 10029.

Sharon Nirenberg (S)

Department of Scientific Computing and Data Science, Icahn School of Medicine at Mount Sinai, New York NY 10029.

Patricia Kovatch (P)

Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York NY 10029.
Department of Scientific Computing and Data Science, Icahn School of Medicine at Mount Sinai, New York NY 10029.

Joseph Goldfarb (J)

Department of Pharmacological Sciences, and Institute for Systems Biomedicine, Icahn School of Medicine at Mount Sinai, New York NY 10029.

Lori Croft (L)

Division of Cardiology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York NY 10029.

Maryann A McLaughlin (MA)

Division of Cardiology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York NY 10029.

Edgar Argulian (E)

Division of Cardiology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York NY 10029.

Stamatios Lerakis (S)

Division of Cardiology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York NY 10029.

Jagat Narula (J)

Division of Cardiology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York NY 10029.

Adolfo García-Sastre (A)

Department of Microbiology and Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York NY 10029.
Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York NY 10029.
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York NY 10029.

Ravi Iyengar (R)

Department of Pharmacological Sciences, and Institute for Systems Biomedicine, Icahn School of Medicine at Mount Sinai, New York NY 10029.

Classifications MeSH